Effects of NKTR-255, a polymer conjugated human IL-15, on efficacy of CAR T cell immunotherapy in a preclinical lymphoma model



¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, ²Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, WA, ³Technical University of Munich, Munich, Germany, ⁴Nektar Therapeutics, San Francisco, CA, ⁵Department of Medicine, University of Washington, Seattle, WA

Background


Chou et al_EHA 2019 NTKR-255 poster_For upload.pdf 1 6/11/2019 3:43:45 PM

Immunotherapy with CD19 CAR T cells achieves complete or partial remission in a fraction of patients with B cell malignancies, but disease progression remains common. IL-15 promotes T cell proliferation and survival, and may enhance CAR T cell efficacy. However, exploiting native IL-15 is challenging due to its unfavorable pharmacokinetics and tolerability. In contrast, NKTR-255 is a polymer-conjugated IL-15 that retains binding affinity to IL-15Rα, maintaining full spectrum of IL-15 biology. NKTR-255 also exhibits improved pharmacokinetics thereby providing sustained pharmacodynamic responses without the need for daily dosing. We investigated the effects of NKTR-255 on human CD19 CAR T cells both in vitro and in an in vivo xenogeneic B-cell lymphoma model.

Methods


cytometry.

T cells expressing a CD19/4-1BB/CD3 ζ CAR were generated from healthy donors. Briefly, CD4 and CD8 T cells were isolated and separately transduced with CD19 CAR lentiviral vector (Fig.1), transduced cells were sorted then expanded with LCL (lymphoblastoid B-cell line) cells for 14-16 days. For in vitro studies, CAR T cells were incubated with NKTR-255. STAT5 phosphorylation and CFSE dilution were assessed by flow cytometry. For *in vivo* studies, NSG mice received 5x10⁵ Raji lymphoma cells IV on day (D)-7 and a subtherapeutic dose (0.8x10⁶) of CAR T cells (1:1 CD4:CD8) on D0. NKTR-255 (0.03, 0.1 or 0.3 mg/kg) was infused IV weekly starting on D-1, 7, or 14. Tumor-free mice were rechallenged with Raji cells. Tumors were assessed by bioluminescence imaging.



Results A **-■** |L15 CD8 CAR T cells NKTR-255IL-15EC500.960.13(ng/ml) IL-15Rα -**I**L15 CD4 CAR T cells NKTR-255IL-15EC500.840.16 (ng/ml) IL-15Rα Log concentration (ng/ml) Figure 2: CAR T cells express IL-15Rα and exhibit dose-dependent phosphorylation of STAT5 and proliferation in response to NKTR-255. CD8 and CD4 CAR T cells were generated from healthy donors and assayed on day 15. (A) IL-15Rα expression was measured by flow cytometry. CD8 (green line), CD4 (blue line), FMO (filled gray) and isotype control (dashed line) are shown. (B) CAR T cells were stimulated with various concentrations of NKTR-255 or IL-15 for 20 minutes. Phosphorylation

Cassie K. Chou^{1,2}, Simon Frassle³, Rachel N. Steinmetz¹, Reed M. Hawkins¹, Tinh-Doan Phi¹, Dirk H. Busch³, Takahiro Miyazaki⁴, Mario Marcondes⁴, Stanley R. Riddell^{1,5}, Cameron J. Turtle^{1,5}



of STAT5 was measured by flow cytometry. (C) CAR T cells were labeled with CFSE and incubated with various concentrations of NKTR-255 of IL15 for 4 days. Proliferation was assayed by flow

